Safety and maximum tolerated dose of superselective intraarterial cerebral infusion of bevacizumab after osmotic blood-brain barrier disruption for recurrent malignant glioma

Clinical article

View More View Less
  • 1 Departments of Neurosurgery,
  • | 2 Neuroradiology,
  • | 3 Medical Oncology,
  • | 4 Nuclear Medicine, and
  • | 5 Biostatistics and Epidemiology, Weill Cornell Brain Tumor Center, Weill Cornell Medical College of Cornell University, New York, New York
Restricted access

Purchase Now

USD  $45.00

JNS + Pediatrics - 1 year subscription bundle (Individuals Only)

USD  $515.00

JNS + Pediatrics + Spine - 1 year subscription bundle (Individuals Only)

USD  $612.00
Print or Print + Online

Object

The authors assessed the safety and maximum tolerated dose of superselective intraarterial cerebral infusion (SIACI) of bevacizumab after osmotic disruption of the blood-brain barrier (BBB) with mannitol in patients with recurrent malignant glioma.

Methods

A total of 30 patients with recurrent malignant glioma were included in the current study.

Results

The authors report no dose-limiting toxicity from a single dose of SIACI of bevacizumab up to 15 mg/kg after osmotic BBB disruption with mannitol. Two groups of patients were studied; those without prior bevacizumab exposure (naïve patients; Group I) and those who had received previous intravenous bevacizumab (exposed patients; Group II). Radiographic changes demonstrated on MR imaging were assessed at 1 month postprocedure. In Group I patients, MR imaging at 1 month showed a median reduction in the area of tumor enhancement of 34.7%, a median reduction in the volume of tumor enhancement of 46.9%, a median MR perfusion (MRP) reduction of 32.14%, and a T2-weighted/FLAIR signal decrease in 9 (47.4%) of 19 patients. In Group II patients, MR imaging at 1 month showed a median reduction in the area of tumor enhancement of 15.2%, a median volume reduction of 8.3%, a median MRP reduction of 25.5%, and a T2-weighted FLAIR decrease in 0 (0%) of 11 patients.

Conclusions

The authors conclude that SIACI of mannitol followed by bevacizumab (up to 15 mg/kg) for recurrent malignant glioma is safe and well tolerated. Magnetic resonance imaging shows that SIACI treatment with bevacizumab can lead to reduction in tumor area, volume, perfusion, and T2-weighted/FLAIR signal.

Abbreviations used in this paper:

BBB = blood-brain barrier; DLT = dose-limiting toxicity; FDG = [18F]fluorodeoxyglucose; GBM = glioblastoma multiforme; IA = intraarterial; IV = intravenous; KPS = Karnofsky Performance Scale; MRP = MR perfusion; MTD = maximum tolerated dose; PE = pulmonary embolism; SIACI = superselective intraarterial cerebral infusion; SUV = standard uptake value; VEGF = vascular endothelial growth factor.

JNS + Pediatrics - 1 year subscription bundle (Individuals Only)

USD  $515.00

JNS + Pediatrics + Spine - 1 year subscription bundle (Individuals Only)

USD  $612.00
  • 1

    Abrey LE: Bevacizumab in recurrent malignant glioma. Curr Neurol Neurosci Rep 8:233234, 2008

  • 2

    Bullard DE, & Bigner DD: Blood-brain barrier disruption in immature Fischer 344 rats. J Neurosurg 60:743750, 1984

  • 3

    Bullard DE, , Bigner SH, & Bigner DD: Comparison of intravenous versus intracarotid therapy with 1,3-bis(2-chloroethyl)-1-nitrosourea in a rat brain tumor model. Cancer Res 45:52405245, 1985

    • Search Google Scholar
    • Export Citation
  • 4

    Cloughesy TF, , Black KL, , Gobin YP, , Farahani K, , Nelson G, & Villablanca P, et al.: Intra-arterial Cereport (RMP-7) and carboplatin: a dose escalation study for recurrent malignant gliomas. Neurosurgery 44:270279, 1999

    • Search Google Scholar
    • Export Citation
  • 5

    Cloughesy TF, , Gobin YP, , Black KL, , Viñuela F, , Taft F, & Kadkhoda B, et al.: Intra-arterial carboplatin chemotherapy for brain tumors: a dose escalation study based on cerebral blood flow. J Neurooncol 35:121131, 1997

    • Search Google Scholar
    • Export Citation
  • 6

    Guillaume DJ, , Doolittle ND, , Gahramanov S, , Hedrick NA, , Delashaw JB, & Neuwelt EA: Intra-arterial chemotherapy with osmotic blood-brain barrier disruption for aggressive oligodendroglial tumors: results of a phase I study. Neurosurgery 66:4858, 2010

    • Search Google Scholar
    • Export Citation
  • 7

    Gutin PH, , Iwamoto FM, , Beal K, , Mohile NA, , Karimi S, & Hou BL, et al.: Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas. Int J Radiat Oncol Biol Phys 75:156163, 2009

    • Search Google Scholar
    • Export Citation
  • 8

    Hall WA, , Doolittle ND, , Daman M, , Bruns PK, , Muldoon L, & Fortin D, et al.: Osmotic blood-brain barrier disruption chemotherapy for diffuse pontine gliomas. J Neurooncol 77:279284, 2006

    • Search Google Scholar
    • Export Citation
  • 9

    Iwadate Y, , Namba H, , Saegusa T, & Sueyoshi K: Intra-arterial mannitol infusion in the chemotherapy for malignant brain tumors. J Neurooncol 15:185193, 1993

    • Search Google Scholar
    • Export Citation
  • 10

    Iwadate Y, , Namba H, & Sueyoshi K: Intra-arterial ACNU and cisplatin chemotherapy for the treatment of glioblastoma multiforme. Neurol Med Chir (Tokyo) 35:598603, 1995

    • Search Google Scholar
    • Export Citation
  • 11

    Kosaka N, , Tsuchida T, , Uematsu H, , Kimura H, , Okazawa H, & Itoh H: 18F-FDG PET of common enhancing malignant brain tumors. AJR Am J Roentgenol 190:W365W369, 2008

    • Search Google Scholar
    • Export Citation
  • 12

    Kroll RA, & Neuwelt EA: Outwitting the blood-brain barrier for therapeutic purposes: osmotic opening and other means. Neurosurgery 42:10831100, 1998

    • Search Google Scholar
    • Export Citation
  • 13

    Macdonald DR, , Cascino TL, , Schold SC Jr, & Cairncross JG: Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8:12771280, 1990

    • Search Google Scholar
    • Export Citation
  • 14

    Miyagami M, , Tsubokawa T, , Tazoe M, & Kagawa Y: Intra-arterial ACNU chemotherapy employing 20% mannitol osmotic blood-brain barrier disruption for malignant brain tumors. Neurol Med Chir (Tokyo) 30:582590, 1990

    • Search Google Scholar
    • Export Citation
  • 15

    Namba H, , Kobayashi S, , Iwadate Y, , Saegusa T, , Sato A, & Watanabe Y, et al.: Assessment of the brain areas perfused by superselective intra-arterial chemotherapy using single photon emission computed tomography with technetium-99mhexamethyl-propyleneamine oxime—technical note. Neurol Med Chir (Tokyo) 34:832835, 1994

    • Search Google Scholar
    • Export Citation
  • 16

    Neuwelt EA, , Abbott NJ, , Drewes L, , Smith QR, , Couraud PO, & Chiocca EA, et al.: Cerebrovascular Biology and the various neural barriers: challenges and future directions. Neurosurgery 44:604609, 1999

    • Search Google Scholar
    • Export Citation
  • 17

    Neuwelt EA, , Barnett PA, , Hellström KE, , Hellström I, , McCormick CI, & Ramsey FL: Effect of blood-brain barrier disruption on intact and fragmented monoclonal antibody localization in intracerebral lung carcinoma xenografts. J Nucl Med 35:18311841, 1994

    • Search Google Scholar
    • Export Citation
  • 18

    Neuwelt EA, , Barnett PA, , McCormick CI, , Frenkel EP, & Minna JD: Osmotic blood-brain barrier modification: monoclonal antibody, albumin, and methotrexate delivery to cerebrospinal fluid and brain. Neurosurgery 17:419423, 1985

    • Search Google Scholar
    • Export Citation
  • 19

    Neuwelt EA, & Dahlborg SA: Chemotherapy administered in conjunction with osmotic blood-brain barrier modification in patients with brain metastases. J Neurooncol 4:195207, 1987

    • Search Google Scholar
    • Export Citation
  • 20

    Neuwelt EA, , Gilmer-Knight K, , Lacy C, , Nicholson HS, , Kraemer DF, & Doolittle ND, et al.: Toxicity profile of delayed high dose sodium thiosulfate in children treated with carboplatin in conjunction with blood-brain-barrier disruption. Pediatr Blood Cancer 47:174182, 2006

    • Search Google Scholar
    • Export Citation
  • 21

    Neuwelt EA, , Guastadisegni PE, , Várallyay P, & Doolittle ND: Imaging changes and cognitive outcome in primary CNS lymphoma after enhanced chemotherapy delivery. AJNR Am J Neuroradiol 26:258265, 2005

    • Search Google Scholar
    • Export Citation
  • 22

    Neuwelt EA, & Hill SA: Neurosurgery: chemotherapy in conjunction with blood-brain barrier modification in patients with cerebral metastasis. West J Med 145:86, 1986

    • Search Google Scholar
    • Export Citation
  • 23

    Neuwelt EA, , Howieson J, , Frenkel EP, , Specht HD, , Weigel R, & Buchan CG, et al.: Therapeutic efficacy of multiagent chemotherapy with drug delivery enhancement by blood-brain barrier modification in glioblastoma. Neurosurgery 19:573582, 1986

    • Search Google Scholar
    • Export Citation
  • 24

    Neuwelt EA, , Minna J, , Frenkel E, , Barnett PA, & McCormick CI: Osmotic blood-brain barrier opening to IgM monoclonal antibody in the rat. Am J Physiol 250:R875R883, 1986

    • Search Google Scholar
    • Export Citation
  • 25

    Neuwelt EA, , Specht HD, & Hill SA: Permeability of human brain tumor to 99mTc-gluco-heptonate and 99mTc-albumin. Implications for monoclonal antibody therapy. J Neurosurg 65:194198, 1986

    • Search Google Scholar
    • Export Citation
  • 26

    Riina HA, , Fraser JF, , Fralin S, , Knopman J, , Scheff RJ, & Boockvar JA: Superselective intraarterial cerebral infusion of bevacizumab: a revival of interventional neuro-oncology for malignant glioma. J Exp Ther Oncol 8:145150, 2009

    • Search Google Scholar
    • Export Citation
  • 27

    Riina HA, , Knopman J, , Greenfield JP, , Fralin S, , Gobin YP, & Tsiouris AJ, et al.: Balloon-assisted superselective intra-arterial cerebral infusion of bevacizumab for malignant brainstem glioma. A technical note. Interv Neuroradiol 16:7176

    • Search Google Scholar
    • Export Citation
  • 28

    Shapiro M, , Babb J, , Becske T, & Nelson PK: Safety and efficacy of adjunctive balloon remodeling during endovascular treatment of intracranial aneurysms: a literature review. AJNR Am J Neuroradiol 29:17771781, 2008

    • Search Google Scholar
    • Export Citation
  • 29

    Stewart DJ, , Benjamin RS, , Zimmerman S, , Caprioli RM, , Wallace S, & Chuang V, et al.: Clinical pharmacology of intraarterial cis-diamminedichloroplatinum(II). Cancer Res 43:917920, 1983

    • Search Google Scholar
    • Export Citation
  • 30

    Tyler JL, , Yamamoto YL, , Diksic M, , Théron J, , Villemure JG, & Worthington C, et al.: Pharmacokinetics of superselective intra-arterial and intravenous [11C]BCNU evaluated by PET. J Nucl Med 27:775780, 1986

    • Search Google Scholar
    • Export Citation
  • 31

    Uesaka T, , Shono T, , Suzuki SO, , Nakamizo A, , Niiro H, & Mizoguchi M, et al.: Expression of VEGF and its receptor genes in intracranial schwannomas. J Neurooncol 83:259266, 2007

    • Search Google Scholar
    • Export Citation
  • 32

    Vredenburgh JJ, , Desjardins A, , Herndon JE II, , Dowell JM, , Reardon DA, & Quinn JA, et al.: Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 13:12531259, 2007

    • Search Google Scholar
    • Export Citation
  • 33

    Vredenburgh JJ, , Desjardins A, , Reardon DA, & Friedman HS: Experience with irinotecan for the treatment of malignant glioma. Neuro Oncol 11:8091, 2009

    • Search Google Scholar
    • Export Citation
  • 34

    Wang CH, , Rockhill JK, , Mrugala M, , Peacock DL, , Lai A, & Jusenius K, et al.: Prognostic significance of growth kinetics in newly diagnosed glioblastomas revealed by combining serial imaging with a novel biomathematical model. Cancer Res 69:91339140, 2009

    • Search Google Scholar
    • Export Citation
  • 35

    Weller M, & Yung WK: Bevacizumab—news from the fast lane?. Neuro Oncol 10:647, 2008

  • 36

    Wen PY, , Macdonald DR, , Reardon DA, , Cloughesy TF, , Sorensen AG, & Galanis E, et al.: Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28:19631972, 2010

    • Search Google Scholar
    • Export Citation
  • 37

    Zuniga RM, , Torcuator R, , Jain R, , Anderson J, , Doyle T, & Ellika S, et al.: Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan. J Neurooncol 91:329336, 2009

    • Search Google Scholar
    • Export Citation

Metrics

All Time Past Year Past 30 Days
Abstract Views 1114 258 24
Full Text Views 379 53 12
PDF Downloads 202 47 13
EPUB Downloads 0 0 0